Acasti Pharma Inc
For the period ended Dec 31, 2023. Filed Feb 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 12, 2024
GRCE$1.86-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Statements of Cash Flows
| Nine months ended | ||
|---|---|---|
| December 31,2023 | December 31,2022 | |
| (Expressed in thousands) | $ | $ |
| Cash flows used in operating activities: | ||
| Net loss for the period | (9,687) | (13,342) |
| Adjustments: | ||
| Depreciation of equipment | 10 | 116 |
| Gain on sale of equipment | (58) | — |
| Stock-based compensation | 684 | 1,489 |
| Change in fair value of warrant liabilities | 1,701 | (10) |
| Income tax recovery | (943) | (671) |
| Unrealized foreign exchange (gain) loss | — | (28) |
| Write-off of equipment | 32 | 31 |
| Changes in operating assets and liabilities: | ||
| Receivables | (157) | (268) |
| Prepaid expenses | (213) | (382) |
| Trade and other payables | (1,591) | 478 |
| Operating lease right of use asset | (23) | — |
| Net cash used in operating activities | (10,245) | (12,587) |
| Cash flows from investing activities: | ||
| Acquisition of equipment | — | (9) |
| Proceeds from sale of equipment | 110 | — |
| Acquisition of short-term investments | (6,554) | (5,015) |
| Maturity of short-term investments | — | 13,185 |
| Net cash (used in) provided by investing activities | (6,444) | 8,161 |
| Cash flows from financing activities: | ||
| Net proceeds from issuance of common shares and warrants from private placement | 7,338 | — |
| Proceeds from issuance of common shares from exercise of stock options | 21 | — |
| Net proceeds from shares issuance under the at-the-market (ATM) program | — | 304 |
| Net cash provided by financing activities | 7,359 | 304 |
| Effect of exchange rate fluctuations on cash and cash equivalents | — | 24 |
| Net decrease in cash and cash equivalents | (9,330) | (4,098) |
| Cash and cash equivalents, beginning of period | 27,875 | 30,339 |
| Cash and cash equivalents, end of period | 18,545 | 26,241 |
| Cash and cash equivalents are comprised of: | ||
| Cash | 2,060 | 26,241 |
| Cash equivalents | 16,485 | — |
See accompanying notes to unaudited interim consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.